Omada Health, Inc. (NASDAQ: OMDA) President Shao Wei-Li reported a sale of 2,829 shares of the company's common stock on April 8, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The transaction produced proceeds of $35,945, calculated from a weighted average sale price of $12.7062 per share. Execution prices in the trade ranged from $12.51 to $13.05.
Following the disposition, Shao Wei-Li retains direct ownership of 328,850 shares of Omada Health common stock. The shares have been under pressure recently: the stock is trading at $11.41 and has declined 50% over the past six months from a 52-week high of $28.40.
The sale was completed pursuant to a pre-established 10b5-1 trading plan that was adopted on August 15, 2025. Such plans allow insiders to sell shares according to predetermined terms and are commonly used to avoid questions about opportunistic trading around material events.
Recent company results
Omada reported a notable set of results for the fourth quarter of 2025 and for the full year. The company posted earnings per share of $0.08 for the quarter, compared with an expected -$0.06, representing a 233.33% surprise to the upside. Revenue for the quarter was $76 million, up 58% year-over-year. The company also disclosed additional growth metrics that included 54% revenue growth, 55% member growth, and gross margins of 72.6%.
Importantly, Omada recorded its first instance of GAAP profitability in the reported quarter and generated positive operating cash flow for the full year.
Analyst moves and valuation commentary
Despite the operational improvements and profitable quarter, two research firms adjusted their price targets downward. Evercore ISI reduced its target to $20 from $25 while retaining an Outperform rating. BMO Capital lowered its target to $18 from $27, citing valuation pressure in the healthcare IT sector, though it also maintained an Outperform rating and said it remained encouraged by Omada’s recent performance and growth trajectory.
Separately, InvestingPro analysis cited in the filing indicates the stock appears slightly undervalued based on its Fair Value metrics and references broader research coverage including Pro Research Reports on OMDA and more than 1,400 U.S. equities.
Context and implications
The insider sale was made under a prearranged plan and does not in itself establish new information about company operations. At the same time, the combination of a meaningful stock decline over six months, recent analyst target reductions tied to sector valuation pressure, and the company’s first GAAP profitability creates a mixed backdrop for investors assessing Omada’s shares.